Clinical trial
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (ELOQUENT - 2)
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (ELOQUENT - 2)
ClinicalTrials.gov ID: NCT01239797
Sponsor: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb (Responsible Party)
Last Update Posted: 2022-06-01
Brief Summary:
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).
Official Title:
Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)
Intervention / Treatment:
- Drug: Lenalidomide
- Drug: Dexamethasone
- Drug: Dexamethasone (Oral)
- Drug: Dexamethasone (IV)
- Biological: Elotuzumab (BMS-901608; HuLuc63)
| Category | Value |
|---|---|
| Study Start (Actual) |
2011-06-20
|
| Primary Completion (Actual) |
2014-09-02
|
| Study Completion (Actual) |
2021-04-21
|
| Enrollment (Actual) | 646 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
CA204-004
2010-020347-12 (EudraCT Number) |